Conference on Cancer Diagnostics to be Held from September 27 to 30, 2010

The American Association for Cancer Research will host its Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development from Sept. 27-30, 2010, at the Sheraton Denver Downtown in Denver, Colo.

Recent advances in genomics, proteomics, molecular imaging and other new technologies are leading to a molecularly based reclassification of cancer. These approaches allow for a more precise understanding of a patient's tumor and a more personalized, targeted approach to therapy.

"This emerging understanding, together with the enhanced ability to characterize tumors from individual patients, creates many opportunities for improved treatment of malignancy and accelerated development of new therapeutics," said Program Chairperson Gordon B. Mills, M.D., Ph.D., chair of the department of systems biology at the University of Texas MD Anderson Cancer Center.

Mills will host a press conference on some of the new diagnostic methods under development on Sept. 28, at 1:00 p.m. MT.

The following are press releases, which are based on research that will be highlighted during the press conference:

  • Triple-negative Breast Cancers May Have Unique Therapeutic Target
  • Circulating Tumor Cells Can Provide "Real-time" Information on Patient's Current Disease State
  • Biomarker Panel Identifies Prostate Cancer with 90 Percent Accuracy
  • New Biomarkers Discovered for Pancreatic Cancer and Mesothelioma

The AACR Communication Department is also highlighting the following research, which will be presented at the meeting:

  • African-Americans Equally Likely to Benefit from Erlotinib and Other Targeted Lung Cancer Therapy
  • Novel Test Following Prostate Surgery Could Detect Cancer Recurrence Earlier
  • MicroRNA Panel Provides a More Precise Lung Cancer Diagnosis
  • Screening Tool Can Detect Colorectal Cancer from a Small Blood Sample
  • Novel Biomarker May Predict Response to New VEGF Receptor Inhibitor
  • Nanotechnology Brings Personalized Therapy One Step Closer to Reality
  • Dual-capture CTC Chip Efficiently Captures Breast Cancer Cells
  • Method to Detect Bladder Cancer Earlier is Under Development
  • c-Met May Be a Biomarker for Metastatic Hepatocellular Carcinoma

Source: http://www.aacr.org/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.